Biovie (BIVI) Cash from Operations (2013 - 2026)
Biovie (BIVI) posted Cash from Operations of 7441609.0 for Q1 2026, down 67.69% sequentially from 4437717.0 in Q4 2025, and down 493.67% YoY from 1890340.36 in Q1 2025.
Biovie (BIVI) Cash from Operations (2013 - 2026) Analysis & Trends
Biovie has reported Cash from Operations for 14 years, with the latest figure at 7441609.0 in Q1 2026.
- Quarterly Cash from Operations fell 493.67% year-over-year to 7441609.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20510667.0 (down 17.71% YoY) and the FY2025 annual result came in at 19025205.0, up 31.92% from the prior year.
- Cash from Operations eased to 7441609.0 in Q1 2026 per BIVI's latest filing, from 4437717.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1253503.0 in Q1 2025 and troughed at 13125753.0 in Q3 2022.
- A 5-year average of 6928335.41 and a median of 5884862.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations jumped 78.58% in 2025, then sank 493.67% in 2026.
- Over 5 years, Cash from Operations stood at 8009228.0 in 2022, then gained by 26.21% to 5909850.0 in 2023, then plunged by 45.26% to 8584779.0 in 2024, then surged by 48.31% to 4437717.0 in 2025, then slumped by 67.69% to 7441609.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 7441609.0, 4437717.0, and 3023874.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | -4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.12 Mn |
| Jun 30, 2026 | -4.12 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | -3.02 Mn |
| Sep 30, 2025 | -3.02 Mn |
| Jun 30, 2025 | -5.61 Mn |
| Jun 30, 2025 | -5.61 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | -8.58 Mn |
| Dec 31, 2024 | -8.58 Mn |
| Sep 30, 2024 | -3.58 Mn |
| Sep 30, 2024 | -3.58 Mn |
| Jun 30, 2024 | -4.01 Mn |
| Jun 30, 2024 | -4.01 Mn |
| Mar 31, 2024 | -5.85 Mn |
| Mar 31, 2024 | -5.85 Mn |